|Bid||31.55 x 1000|
|Ask||31.77 x 2200|
|Day's Range||30.83 - 33.80|
|52 Week Range||6.16 - 36.88|
|Beta (5Y Monthly)||2.19|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 4, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||46.00|
Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed in recent years. However, hedge funds are generally partially hedged and aim at […]
Biotech stocks advanced in the holiday-shortened week, with upside driven mainly by the broader market strength. Reflecting the extreme volatility in the space, a few stocks gyrated wildly in reaction ...
The Zacks Analyst Blog Highlights: Intercept, CymaBay, Amgen, Global Blood Therapeutics and ChemoCentryx
ChemoCentryx (CCXI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
ChemoCentryx (CCXI) announces positive data pivotal study evaluating its lead candidate, avacopan, in patients with ANCA vasculitis, a rare disease affecting small blood vessels.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 26) Allakos Inc (NASDAQ: ALLK ) Alnylam Pharmaceuticals, ...
A set of conclusive findings from a late-stage clinical trial testing ChemoCentryx Inc.’s experimental vasculitis treatment surprised company executives and investors, who now say they are bullish on the sales and pipeline potential of avacopan.
ChemoCentryx (CCXI) is on everyone’s radar Tuesday, with shares flying higher by more than 350% at one point. The ride was instigated by the positive results from the phase 3 ADVOCATE study of Avacopan, an oral 5a receptor inhibitor, used for the treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (ANCA-associated vasculitis).ANCA Associated Vasculitis (AAV) is a rare, grave, and often fatal autoimmune disease causing the destruction and inflammation of small blood vessels that can impact several different organ systems, and often involves the kidneys.The crucial trial achieved both objectives of clinical remission at weeks 26 and 52 with statistical superiority of Avacopan over the standard of care at both time frames, and significantly higher at 52 weeks.5-star H.C. Wainwright analyst Edward White was taken aback by the results, noting, “The superiority finding was a positive surprise. As a reminder, the company is planning to market avacopan on its own in the U.S., and it has already begun its plans, including senior level sales management hires. We believe a field force of MSLs and sales reps of about 50-75 people is appropriate in the U.S. ChemoCentryx expects to file an NDA in 2020, followed by an MAA filing also next year.”Following the positive results, White reiterated a Buy rating on CCXI, while boosting his price target from $23 to $40. (To watch White's track record, click here)White added, "The secondary endpoints’ data thus far look compelling and may be more important for commercialization of Avacopan. We anticipate Avacopan approval and launch in 2021 with sales of $29M in 2021 and $128M in 2022.” Following the positive data results, the analyst also increased the probability of success for Avacopan from 30% to 70%.Although ChemoCentryx has only a few analysts currently throwing the hat in the ring, all are bullish on the stock. CCXI’s analyst consensus rating is a Strong Buy, with all 3 analysts giving it the thumbs up. The 12-month average price target stands at $29.50, which would have indicated much upside this morning, before the share price’s incredible rally, but now indicates a slight downside. This is partly due to the fact analysts have yet to update their ratings following the run up. In the coming days, though, it remains to be seen, whether CCXI can hold on to today’s massive gains. (See ChemoCentryx’s stock analysis on TipRanks)
Benzinga Pro's Stocks To Watch For Tuesday Best Buy (BBY) - Reported strong Q3 results, Q4 guidance and raised FY20 guidance. Shares were up 4% following the report. ChemoCentryx (CCXI) - Tuesday morning's ...
ChemoCentryx, Inc., (CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the 31st Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2019 at 2:30 p.m. ET. The conference will be held at the Lotte New York Palace in New York, NY. A live audio webcast of the presentations can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com.
Futures: The stock market hit new highs Monday, but the VIX fear gauge hit a low. Palo Alto Networks, Ambarella and Nutanix were big earnings movers late. ChemoCentryx spiked on drug news.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 25.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam ...
FDA Says CBD Can Hurt Your Liver Potentially speaking. Potentially, anything can hurt your liver, but that isn’t stopping the Food and Drug Administration from singling out cannabidiol (CBD), the nonpsychoactive cannabinoid generally recognized as safe by most people, but not officially so by the FDA. The compound is now sold in pharmacies including CVS […]The post Market Morning: CBD Warning, Chemocentryx Win, Huge Tory Majority, Amazon Injuries appeared first on Market Exclusive.
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and ChemoCentryx, Inc., (CCXI) today announced positive topline data from the pivotal phase-III ADVOCATE trial of avacopan, an orally administered selective complement 5a receptor inhibitor, for the treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (ANCA-associated vasculitis or ANCA vasculitis).
ChemoCentryx Inc. shares rocketed 300% higher in after-hours trading Monday after the pharmaceutical company announced the "transformational result" from a drug study seeking to help acute vasculitis sufferers. ChemoCentryx ended Monday's session with a per-share price of $8.06, giving it a market value of $469.6 million, according to FactSet, before shooting to more than $32 a share in after-hours trading. The phase 3 study of 331 patients with anti-neutrophil cytoplasmic antibody-associated vasculitis met its primary endpoints, which was to show remission of the vasculitis at 26 weeks and sustained remission after a year at rates better than the current treatment for the disease, which is an inflammation of blood vessels that can inhibit blood flow. ANCA vasculitis is a form of the disease that can destroy organs, especially the kidney. The study of a drug called avacopan also reached multiple secondary endpoints, including improved quality of life and kidney function for patients with renal disease. "This is the transformational result that clinicians and patients all over the world had been hoping for," Dr. David Jayne, director of the Vasculitis and Lupus Clinic at Addenbrooke's Hospital in Cambridge, said in Monday's announcement. "The ADVOCATE trial demonstrated clearly that avacopan effectively brought patients into a state of remission for their acute vasculitis symptoms and kept them there for the entire period of this study."
ChemoCentryx, Inc., (CCXI) and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced positive topline data from the pivotal Phase III ADVOCATE trial of avacopan, an orally-administered selective complement 5a receptor inhibitor, for the treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (ANCA-associated vasculitis or ANCA vasculitis). This global study, in which a total of 331 patients with acute ANCA vasculitis were enrolled, met both of its primary endpoints, disease remission at 26 weeks and sustained remission at 52 weeks, as assessed by the Birmingham Vasculitis Activity Score, or BVAS.
Alexandria Real Estate Equities has submitted plans for a 1.6 million-square-foot project in San Carlos, part of its potentially transformative Alexandria District for Science & Technology.
Thomas Schall has been the CEO of ChemoCentryx, Inc. (NASDAQ:CCXI) since 1997. This report will, first, examine the...
ChemoCentryx, Inc., (CCXI), today announced presentations of its lead drug candidates avacopan, a complement 5a receptor inhibitor, and CCX140, an inhibitor of the chemokine receptor known as CCR2, during the American Society of Nephrology (ASN) Kidney Week 2019, the world's premier nephrology meeting, being held November 5-10, 2019 in Washington, DC. Focal Segmental Glomerulosclerosis (FSGS) is a rare disease that attacks the kidney's filtering units (glomeruli), causing serious scarring which leads to permanent kidney damage and even failure.
ChemoCentryx (CCXI) delivered earnings and revenue surprises of 21.43% and 35.07%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?